CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

9774	Companies
195618	Keywords
126599	Articles
103991	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 05/20/2025 at 07:30, 8 months 10 days ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 8 months 23 days ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 05/07/2025 at 07:35, 8 months 23 days ago

CROSSJECT : Progrès dans la demande d'autorisation EUA pour ZEPIZURE®

FDA ZEPIZURE® BARDA EUA CHEMPACK
PRESS RELEASE

published on 05/07/2025 at 07:30, 8 months 23 days ago

CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
CROSSJECT provides updates on the EUA filing of ZEPIZURE® for FDA Emergency Use Authorization in June 2025, supporting U.S. CHEMPACK program against chemical threats

FDA Crossject ZEPIZURE EUA Filing CHEMPACK Program
BRIEF

published on 03/27/2025 at 07:35, 10 months 3 days ago

CROSSJECT publie ses résultats financiers 2024

Résultats Financiers Partenariats Situation De Trésorerie ZEPIZURE® Dépôt Auprès De La FDA
BRIEF

published on 03/27/2025 at 07:35, 10 months 3 days ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 10 months 3 days ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 10 months 5 days ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
BRIEF

published on 03/25/2025 at 07:35, 10 months 5 days ago

Partenariat stratégique entre CROSSJECT et ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Insuffisance Surrénale
PRESS RELEASE

published on 03/25/2025 at 07:30, 10 months 5 days ago

CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
CROSSJECT renforce sa collaboration avec ETON PHARMACEUTICALS pour le programme ZENEO® Hydrocortisone dans l'insuffisance surrénale, avec des depôts de dossiers prévus à partir de S2 2026

Collaboration Eton Pharmaceuticals Crossject Insuffisance Surrénale ZENEO® Hydrocortisone

Accesswire

Published on 01/30/2026 at 08:35, 3 hours 10 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 3 hours 45 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 9 hours 30 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 11 hours 45 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 12 hours 45 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 10:30, 1 hour 15 minutes ago

ASTA ENERGY SOLUTIONS AG SUCCESSFULLY COMPLETES IPO
Published on 01/30/2026 at 10:08, 1 hour 36 minutes ago

Désastreux pour le climat et l'économie: auto-suisse critique sévèrement le refus d'assouplir les prescriptions CO2
Published on 01/30/2026 at 10:00, 1 hour 45 minutes ago

Appointment of Managing Director of Tradegate BSX
Published on 01/30/2026 at 09:00, 2 hours 44 minutes ago

Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 2 hours 44 minutes ago

Original-Research: q.beyond AG (von NuWays AG): BUY

Les Echos

Published on 01/30/2026 at 08:30, 3 hours 15 minutes ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés
Published on 01/30/2026 at 08:00, 3 hours 45 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/30/2026 at 08:00, 3 hours 45 minutes ago

AMA : Chiffre d'affaires du 4ème trimestre et de l'année 2025
Published on 01/29/2026 at 18:30, 17 hours 15 minutes ago

ALPOU - Groupe POULAILLON chiffre d'affaires trimestriel T1 2025-2026 et Focus sur les activités
Published on 01/29/2026 at 18:07, 17 hours 37 minutes ago

CDA - Mise à disposition de l'URD 2025

View all LES ECHOS COMFI WIRE